GPD1L Antikörper (AA 1-351)
Kurzübersicht für GPD1L Antikörper (AA 1-351) (ABIN5776141)
Target
Alle GPD1L Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 1-351
-
Verwendungszweck
- Human GPD1L antibody
-
Aufreinigung
- Purified
-
Immunogen
- Recombinant human GPD1L (1-351aa) purified from E. coli
-
Isotyp
- IgG1 kappa
-
-
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- Phosphate-Buffered Saline ( pH 7.4) with 0.02 % Sodium Azide, 10 % glycerol
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C,-80 °C
-
Informationen zur Lagerung
- Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.
-
-
- GPD1L (Glycerol-3-Phosphate Dehydrogenase 1-Like (GPD1L))
-
Andere Bezeichnung
- GPD1L
-
Hintergrund
- GPD1L is converts sn-glycerol 3-phosphate to glycerone phosphate. This protein is found in the cytoplasm, associated with the plasma membrane, where it binds the sodium channel, voltage-gated, type V, alpha subunit (SCN5A). GPD1L is thought to affect trafficking of the cardiac sodium current to the cell surface. Mutations in GPD1L are the cause of sudden infant death syndrome (SIDS) and Brugada syndrome type 2, an autosomal dominant tachyarrhythmia.
-
NCBI Accession
- NP_055956
Target
-